Oncolytic Virus Therapy Market Poised to Surge Beyond US$ 250 Million by 2033

By the end of 2023, the oncolytic viral cancer therapy market is predicted to grow at a startling 27% CAGR, valued at US$ 22.86 million, and by 2033, US$ 250 million. This data is from a recent analysis that Future Market Insights published.The governments of a number of emerging economies have taken steps to raise public awareness of the various causes of cancer.

Government agencies in developed and developing countries are conducting education programs to encourage people to seek early cancer diagnosis, which is expected to increase the number of patients who will be eligible for numerous new therapies.

Due to a significant increase in the number of companies that produce cancer medications, the Asia Pacific region will have the highest ownership stake in the oncolytic virus cancer market. The oncolytic virus therapy market is growing in revenue and earnings as countries such as China and Japan introduce breakthroughs into the market.

Get a Sample Copy of the Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-16335

Because of the region’s high incidence of cancer, particularly melanoma cancer, North America is expected to be the most valuable region for the global oncolytic virus cancer market. Increased cancer incidences around the world are creating a positive outlook for the market. In line with this, the therapy’s widespread use in the treatment of a wide range of melanomas, including haematological malignancies, lymphoma, leukaemia, and myeloma, is boosting overall growth.

Key Takeaways:

• The number of articles on oncolytic virus therapy studies has increased by 395% in the last decade.
• In 2022, Japan’s total oncolytic virus cancer market share was US$ 2 Million, and it is expected to rise during the study period.
• North America is expected to grow at the fastest rate during the forecast period, with a CAGR of 29.5%.
• In the United States in 2021, the market value for oncolytic virus therapies was US$ 8.5 Million
• The global oncolytic virus cancer market is expected to be worth US$ 250 Million.

“As oncology takes a turn for the better, healthcare practitioners are implementing highly advanced ways of diagnosing and treating some of the most debilitating cancers, paving way for enhanced adoption of oncolytic virus cancer therapies,” remarks an FMI analyst.

Elevate Strategy: Tap into Analyst Expertise Now:
https://www.futuremarketinsights.com/ask-question/rep-gb-16335

Market Competition

Key players in the Oncolytic Virus Cancer market are Oncolytics Biotech Inc, Amgen Inc., Sorrento Therapeutics, Transgene SA, Daiichi Sankyo Company, Shanghai Sunway Biotech Co, Ltd, Takara Bio Inc., PsiOxus Therapeutics, SillaJen Inc., ViroCure.

• Amgen, based in the United States, agreed to pay $3.7 billion for the biopharma firm ChemoCentryx in August 2022. As a result of this strategic initiative, Amgen will provide access to Tavneos, the company’s critical therapy that has received therapy confirmation in the EU and Japan. Amgen will be able to expand its reach and develop in regions such as Europe and Asia Pacific as a result of this acquisition.
• In April 2021, Bristol Myers Squibb and PsiOxus Therapeutics enlarged their partnership to investigate PsiOxus Therapeutics’ cancer-killing virus. According to the contract, the collaboration will incorporate Bristol’s checkpoint reagent Opdivo and novel resource NG-641 in various types of tumors. PsiOxus’ oncolytic virus ‘enadenotucirev’ is the basis for NG-641.

Key Segments:

By Virus Type:

• Genetically Engineered Oncolytic Viruses
  • Herpes Simplex Virus
  • Adenovirus
  • Vaccinia Virus
• Oncolytic Wild-type Viruses
  • Reovirus
  • Newcastle Disease Virus
  • Vesicular Stomatitis Virus

By Application:

• Solid Tumor
  • Breast Cancer
  • Prostate Cancer
  • Lung Cancer
  • Glioblastoma
• Melanoma
  • Hematological Malignancies
  • Lymphoma
  • Leukemia
  • Myeloma

Unleash Potential: Craft Your Customized Report Now:
https://www.futuremarketinsights.com/customization-available/rep-gb-16335

By End Use:

• Hospitals
• Specialty Clinics
• Cancer Research Institutes

Author By:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Nandini Singh Sawlani   

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube